Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
27.06.25 | 16:15
11,960 Euro
+1,06 % +0,125
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
11,62011,82028.06.
11,63512,01027.06.

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.uniQure N.V. - 8-K, Current Report7
11.06.uniQure ernennt Kylie O'Keefe zur Chief Customer and Strategy Officer9
11.06.uniQure Inc.: uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer353~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025N.V. (NASDAQ: QURE), a leading gene therapy company advancing...
► Artikel lesen
05.06.stifel reiterates buy rating on uniQure stock after CEO meeting7
02.06.uniQure N.V. - 8-K, Current Report2
02.06.uniQure aligns with FDA on Huntington's therapy path2
02.06.uniQure einigt sich mit FDA über Therapieweg für Huntington-Krankheit16
02.06.uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease451~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and...
► Artikel lesen
UNIQURE Aktie jetzt für 0€ handeln
30.05.HC Wainwright maintains Buy rating on uniQure stock, $70 target3
29.05.uniQure Inc.: uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)402~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies...
► Artikel lesen
09.05.uniQure N.V. - 10-Q, Quarterly Report1
09.05.uniQure GAAP EPS of -$0.82 beats by $0.18, revenue of $1.57M misses by $5.14M3
09.05.uniQure N.V. - 8-K, Current Report2
09.05.uniQure Inc.: uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress350~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related...
► Artikel lesen
08.05.Earnings Outlook For uniQure1
05.05.uniQure Inc.: uniQure to Announce First Quarter 2025 Financial Results405~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025N.V. (NASDAQ: QURE), a leading gene therapy company advancing...
► Artikel lesen
22.04.UniQure stock holds $70 target, buoyed by FDA breakthrough nod12
21.04.FDA grants breakthrough status to uniQure's Huntington's disease therapy5
17.04.uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday6
17.04.Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?3
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1